Gary L. Buchschacher
Hematology Oncology | Oncology
4950 W Sunset Blvd
Los Angeles, CA 90027
Los Angeles, CA 90027
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 19 publications
Pembrolizumab plus chemotherapy versus chemotherapy for advanced esophageal cancer: 5-year extended follow-up for the randomized phase III KEYNOTE-590 study.
Journal: ESMO open
Published: July 25, 2025
NSABP FC-11: A phase II study of neratinib plus trastuzumab or neratinib plus cetuximab in patients with "quadruple wild-type" (KRAS/NRAS/BRAF/PIK3CA) metastatic colorectal cancer based on HER2 status: amplified, non-amplified (wild-type), or mutated.
Journal: Cancer chemotherapy and pharmacology
Published: May 14, 2025
Patient-reported Outcomes for Men with Metastatic Castration-resistant Prostate Cancer Who Received Olaparib plus Abiraterone Versus Placebo plus Abiraterone in the Phase 3 PROpel Study.
Journal: European urology oncology
Published: March 28, 2025
Phase II Study of Copanlisib in Patients With PTEN Loss: Results From NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols Z1G and Z1H.
Journal: JCO precision oncology
Published: February 06, 2025
Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study.
Journal: The lancet. Gastroenterology & hepatology
Published: January 10, 2024
Tolerability of Olaparib Combined with Abiraterone in Patients with Metastatic Castration-resistant Prostate Cancer: Further Results from the Phase 3 PROpel Trial.
Journal: European urology oncology
Published: December 18, 2023
Updated efficacy and safety of entrectinib in NTRK fusion-positive non-small cell lung cancer.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: October 04, 2023
Real-World Clinical Outcomes of Bevacizumab-awwb Biosimilar versus Bevacizumab Reference Product in Patients with Metastatic Colorectal Cancer.
Journal: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy
Published: September 08, 2023
A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms: Results from ECOG-ACRIN E1Z11.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: July 29, 2023
Validation of Immunotherapy Response Score as Predictive of Pan-solid Tumor Anti-PD-1/PD-L1 Benefit.
Validation of Immunotherapy Response Score as Predictive of Pan-solid Tumor Anti-PD-1/PD-L1 Benefit.
Journal: Cancer research communications
Published: January 17, 2023
Abiraterone and Olaparib for Metastatic Castration-Resistant Prostate Cancer.
Journal: NEJM evidence
Published: September 01, 2022
Development and validation of an integrative pan-solid tumor predictor of PD-1/PD-L1 blockade benefit.
Journal: Communications medicine
Published: January 25, 2022
Last Updated: 09/26/2026